Drugs / BMS-986442
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05543629 | Oct 2022 → Sep 2024 | non-small cell lung carcinoma | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-03-06 | Agenus Inc. | Results Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024 agenusbio.com ↗
In non-clinical assays, BMS-986442 demonstrated superior immune activation both as monotherapy and in combination with PD-(L)1 blockade compared to conventional TIGIT antibodies. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-03-06 | Agenus Inc. | Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024 agenusbio.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986442 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05543629 ↗ |